311 related articles for article (PubMed ID: 22981547)
1. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.
Geisler BP; Egan BM; Cohen JT; Garner AM; Akehurst RL; Esler MD; Pietzsch JB
J Am Coll Cardiol; 2012 Oct; 60(14):1271-7. PubMed ID: 22981547
[TBL] [Abstract][Full Text] [Related]
2. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension.
Dorenkamp M; Bonaventura K; Leber AW; Boldt J; Sohns C; Boldt LH; Haverkamp W; Frei U; Roser M
Eur Heart J; 2013 Feb; 34(6):451-61. PubMed ID: 23091202
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK.
Gladwell D; Henry T; Cook M; Akehurst R
Appl Health Econ Health Policy; 2014 Dec; 12(6):611-22. PubMed ID: 25086585
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands.
Henry TL; De Brouwer BF; Van Keep MM; Blankestijn PJ; Bots ML; Koffijberg H
J Med Econ; 2015 Jan; 18(1):76-87. PubMed ID: 25367314
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
Chowdhury EK; Reid CM; Zomer E; Kelly DJ; Liew D
Am J Hypertens; 2018 Sep; 31(10):1156-1163. PubMed ID: 30010694
[TBL] [Abstract][Full Text] [Related]
6. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of captopril therapy after myocardial infarction.
Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
[TBL] [Abstract][Full Text] [Related]
9. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
10. Renal denervation in moderate treatment-resistant hypertension.
Ott C; Mahfoud F; Schmid A; Ditting T; Sobotka PA; Veelken R; Spies A; Ukena C; Laufs U; Uder M; Böhm M; Schmieder RE
J Am Coll Cardiol; 2013 Nov; 62(20):1880-6. PubMed ID: 23850901
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings.
Borisenko O; Beige J; Lovett EG; Hoppe UC; Bjessmo S
J Hypertens; 2014 Mar; 32(3):681-92. PubMed ID: 24378998
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of implantable cardioverter-defibrillators.
Sanders GD; Hlatky MA; Owens DK
N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
[TBL] [Abstract][Full Text] [Related]
13. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
[TBL] [Abstract][Full Text] [Related]
14. Incorporating patient-centered outcomes in the analysis of cost-effectiveness: imaging strategies for renovascular hypertension.
Carlos RC; Axelrod DA; Ellis JH; Abrahamse PH; Fendrick AM
AJR Am J Roentgenol; 2003 Dec; 181(6):1653-61. PubMed ID: 14627591
[TBL] [Abstract][Full Text] [Related]
15. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
[TBL] [Abstract][Full Text] [Related]
16. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
McInnes G; Burke TA; Carides G
J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients.
Hayek SS; Abdou MH; Demoss BD; Legaspi JM; Veledar E; Deka A; Krishnan SK; Wilmot KA; Patel AD; Kumar VR; Devireddy CM
Am J Hypertens; 2013 Dec; 26(12):1452-8. PubMed ID: 23934709
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]